SCHEDULE: Paradigm BioCapital Discloses 5.6% Stake in Cidara Therapeutics

Paradigm BioCapital Advisors LP and its affiliates have reported a passive beneficial ownership of 5.6% in Cidara Therapeutics, Inc.'s common stock.

Summary

• Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. collectively reported beneficial ownership of 1,128,613 shares of Cidara Therapeutics, Inc. common stock.
• This aggregate ownership represents 5.6% of Cidara Therapeutics' outstanding common stock.
• Paradigm BioCapital International Fund Ltd., a private investment vehicle managed by Paradigm BioCapital Advisors LP, directly beneficially owns 994,177 shares, accounting for 4.9% of the class.
• The beneficial ownership is based on 20,163,696 shares of common stock outstanding as of approximately June 26, 2025, as reported by Cidara Therapeutics in its Prospectus Supplement filed on June 25, 2025.
• The filing is a Schedule 13G, indicating that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates significant institutional interest and investment in Cidara Therapeutics, which can be a vote of confidence. However, the passive nature of the stake limits the immediate strategic impact.

Positives

• The disclosure of a significant institutional stake by Paradigm BioCapital Advisors LP and its affiliates signals increased institutional interest and potential confidence in Cidara Therapeutics.
• A 5.6% beneficial ownership by a specialized biotech investment firm can be viewed positively by the market, suggesting a belief in the company's long-term prospects.

Negatives

• The filing is a Schedule 13G, which indicates a passive investment, meaning Paradigm BioCapital does not intend to influence or change control of Cidara Therapeutics, limiting immediate strategic impact from this specific filing.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Cidara Therapeutics or the reporting persons regarding the company's future performance or strategic direction.

Industry Context

This filing reflects a typical institutional investment in a biotechnology company, where specialized funds like Paradigm BioCapital Advisors identify and take positions in firms within their sector of expertise. Such disclosures are common in the biotech industry, which often relies on institutional capital for research, development, and commercialization.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may positively influence investor sentiment and potentially the stock price, signaling external validation of the company's value.

Key Dates

Recommendation

While the disclosure of a new significant institutional stake by Paradigm BioCapital is a positive signal, indicating confidence from a specialized biotech investor, this Schedule 13G filing alone does not provide sufficient operational or financial performance details to warrant a 'buy' or 'sell' recommendation. It primarily serves as an ownership update. Investors should 'hold' and await further financial reports or strategic announcements from Cidara Therapeutics to make a more informed decision, while noting the increased institutional interest as a favorable data point.

Keywords

Cidara Therapeutics, Paradigm BioCapital, Biotechnology, Pharmaceuticals, Institutional Ownership, Schedule 13G, Common Stock, Investment, Healthcare